Table 6 Widely used chemotherapeutic regimens with effect against small cell lung cancer [6]

Regimen	Dosage	Application	Cycles/Precautions
CisEto			Every 3 weeks, or after nadir, normal renal function and diuretics are mandatory
Cisplatin	80 mg·m⁻²	i.v. d1
Etoposide	100 mg·m⁻²	i.v. d1–d3
ACO-I after Livingston and Seeber			Every 3 weeks; vincristine dosage has to be adjusted to age; >60 years reduce to 1 mg·m⁻²
Adriamycin	60 mg·m⁻²	i.v. d1
Cyclophosphamide	750 mg·m⁻²	i.v. d1
Vincristine	2 mg·m⁻²	i.v. d1/d8/d16
ACE combination after Klastersky
Adriamycin	45 mg·m⁻²	i.v. d1
Cyclophosphamide	1000 mg·m⁻²	i.v. d1
Etoposide	80 mg·m⁻²	i.v. d1–d3	Every 3 weeks.
EpiCO therapy after Drings			Every 3 weeks; vincristine dosage has to be adjusted to age; >60 years reduce to 1 mg·m⁻²
Epirubicin	70 mg·m⁻²	i.v. d1
Cyclophosphamide	1000 mg·m⁻²	i.v. d1
Vincristine	2 mg·m⁻²	i.v. d1/d8/d16
Carboplatin/etoposide			Every 3 weeks, or after nadir, normal renal function and diuretics are mandatory
Carboplatin	AUC 5	i.v. d1
Etoposide	100 mg·m⁻²	i.v. d1-d3
Paclitaxel/etoposide/carboplatin			Every 3 weeks, steroids to prevent anaphylactic crisis after administration of paclitaxel is mandatory
Paclitaxel	175 mg·m⁻²	i.v. for 3 h
Carboplatin	AUC 5	d4
Etoposide	I–III: 100 mg·m⁻²	i.v. d4
	IV: 100 mg·m⁻²	d1–d3
Cisplatin/irinotecan			Atropine 0.25 mg 1/2 h before irinotecan s.c. Every 4 weeks and/or after nadir; diarrhoea is common
Cisplatin	60 mg·m⁻²	i.v. d1
Irinotecan	60 mg·m⁻²	i.v. d 1, 8,15
Topotecan (second-line)
Topotecan	1.25 mg·m⁻² with subsequent dose adjustment according to haematological toxicity	i.v. d 1–5	Every 3 weeks and/or after reaching normal laboratory values